journal article·2020-05-26

Photothermal Depletion of Cancer-Associated Fibroblasts Normalizes Tumor Stiffness in Desmoplastic Cholangiocarcinoma

Alba Nicolás-Boluda, Javier Vaquero, Gautier Laurent, Gilles Renault, Rana Bazzi, Emmanuel Donnadieu, Stéphane Roux, Laura Fouassier, Florence Gazeau

ACS Nano· Volume 14· Issue 5
Publisher page

Abstract

Physical oncology recognizes tissue stiffness mediated by activation of cancer-associated fibroblasts (CAF) and extracellular matrix remodeling as an active modulator of tumorigenesis, treatment resistance, and clinical outcome. Cholangiocarcinoma (CCA) is a highly aggressive and chemoresistant desmoplastic cancer enriched in CAF. CCA's stroma mechanical properties are considered responsible for its chemoresistant character. To normalize tumor mechanics, we propose a physical strategy based on remotely light-activated nanohyperthermia to modulate the tumor microenvironment. In this study, we report the use of multifunctional iron oxide nanoflowers decorated with gold nanoparticles (GIONF) as efficient nanoheaters to achieve complete tumor regression following three sessions of mild hyperthermia. The preferential uptake of GIONF by CAF allowed targeting this cell population, which resulted in a significant early reduction of tumor stiffness followed by tumor regression. In conclusion, our study highlights a spatially and temporally controlled physical strategy, GIONF-mediated photothermal therapy to deplete CAF and normalize the tumor mechanics that may apply to desmoplastic cancer and CCA treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Oral and Maxillofacial Pathology · Nanoplatforms for cancer theranostics · Cholangiocarcinoma and Gallbladder Cancer Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratoire Matière et Systèmes Complexes (MSC), Université de Paris, CNRS-UMR 7057, Paris 75013, France

Institut Cochin, Université de Paris, INSERM U1016/CNRS UMR 8104, Paris 75014, France

Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, Paris 75012, France

Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III, Madrid, Spain

Institut UTINAM, CNRS UMR 6213, Université Bourgogne Franche-Comté, Besançon 25010, France

Funding

Agence Nationale de la Recherche · H2020 Future and Emerging Technologies · H2020 Industrial Leadership · European Cooperation in Science and Technology

References (41)

Show source-provided references
1. 10.1038/nrgastro.2016.5110.1038/nrgastro.2016.51 ↗
2. 10.1056/NEJMoa090872110.1056/NEJMoa0908721 ↗
3. 10.1111/liv.1409810.1111/liv.14098 ↗
4. 10.1002/hep.2657710.1002/hep.26577 ↗
5. 10.1172/JCI021522310.1172/JCI0215223 ↗
6. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
7. 10.1158/0008-5472.CAN-03-147210.1158/0008-5472.CAN-03-1472 ↗
8. 10.1038/nrc.2016.7310.1038/nrc.2016.73 ↗
9. 10.1245/s10434-012-2343-110.1245/s10434-012-2343-1 ↗
10. 10.1158/0008-5472.CAN-12-213010.1158/0008-5472.CAN-12-2130 ↗
11. 10.1002/wnan.144910.1002/wnan.1449 ↗
12. 10.1002/smll.20130292410.1002/smll.201302924 ↗
13. 10.1021/acsami.6b0994210.1021/acsami.6b09942 ↗
14. 10.1039/C4NR00708E10.1039/C4NR00708E ↗
15. 10.7150/thno.3023810.7150/thno.30238 ↗
16. 10.1021/jp302547810.1021/jp3025478 ↗
17. 10.1021/nn304477s10.1021/nn304477s ↗
18. 10.1002/smll.20140028110.1002/smll.201400281 ↗
19. 10.1002/smll.20160203010.1002/smll.201602030 ↗
20. 10.1002/smll.20130230310.1002/smll.201302303 ↗
21. 10.1073/pnas.191173411610.1073/pnas.1911734116 ↗
22. 10.1021/ja208433810.1021/ja2084338 ↗
23. 10.1039/c3nr00012e10.1039/c3nr00012e ↗
24. 10.1103/PhysRevB.71.12541110.1103/PhysRevB.71.125411 ↗
25. 10.1021/jp027048e10.1021/jp027048e ↗
26. 10.1186/1556-276X-9-45410.1186/1556-276X-9-454 ↗
27. 10.21037/tgh.2019.10.1710.21037/tgh.2019.10.17 ↗
28. 10.3748/wjg.v22.i37.825710.3748/wjg.v22.i37.8257 ↗
29. 10.1158/1078-0432.CCR-13-004310.1158/1078-0432.CCR-13-0043 ↗
30. 10.7150/thno.1757410.7150/thno.17574 ↗
31. 10.1111/jce.1270910.1111/jce.12709 ↗
32. 10.3748/wjg.v17.i14.187410.3748/wjg.v17.i14.1874 ↗
33. 10.1016/j.cell.2009.10.02710.1016/j.cell.2009.10.027 ↗
34. 10.18632/oncotarget.851510.18632/oncotarget.8515 ↗
35. 10.1002/hep.2410810.1002/hep.24108 ↗
36. 10.1016/0360-3016(84)90379-110.1016/0360-3016(84)90379-1 ↗
37. 10.1021/nn405356r10.1021/nn405356r ↗
38. 10.1016/j.jconrel.2015.03.02310.1016/j.jconrel.2015.03.023 ↗
39. 10.1016/j.jconrel.2014.03.01610.1016/j.jconrel.2014.03.016 ↗
40. 10.1038/oncsis.2017.5410.1038/oncsis.2017.54 ↗
41. 10.1021/acsnano.5b0724910.1021/acsnano.5b07249 ↗